Ventas, Inc. - VTR STOCK NEWS

Ventas, Inc. reports Q4 and full-year 2020 results, highlighting the positive performance of its Office and Triple-Net Healthcare businesses. Senior Housing Operating Portfolio (SHOP) occupancy declined due to the COVID-19 pandemic but is expected to improve as vaccination rates increase. The company ensured financial strength and flexibility, prioritized health and safety, and received ESG recognitions. Q1 2021 guidance reflects the ongoing impact of the pandemic.

Ventas, Inc. (NYSE: VTR) has appointed Maurice Smith, CEO of Health Care Service Corporation, as an independent member of its Board of Directors. Smith brings over 25 years of healthcare experience, having been recognized as one of Modern Healthcare's 100 Most Influential People. His expertise will be valuable as Ventas navigates post-Covid-19 challenges. With this appointment, the Board now comprises 12 directors, 11 of whom are independent, ensuring diverse perspectives and solid governance.

Ventas (NYSE: VTR) has successfully closed a new four-year $2.75 billion unsecured credit facility, which was oversubscribed with support from 24 financial institutions. This facility enhances liquidity, extends debt maturities, and reduces borrowing costs, with initial pricing set at 82.5 basis points over LIBOR. Nearly $2.7 billion remains available for borrowing. Additionally, the facility includes a $1 billion accordion feature and links borrowing costs to sustainability metrics, reflecting Ventas's commitment to ESG leadership.

Ventas, Inc. (NYSE: VTR) will announce its fourth quarter and full year 2020 earnings on February 18, 2021, before the market opens. A conference call will take place on the same day at 10:00 a.m. ET. Investors can participate via a dial-in number or a live webcast on the company's Investor Relations website. Ventas operates in the healthcare real estate sector, managing around 1,200 properties as of September 30, 2020. The company focuses on generating consistent cash flows and returns, leveraging its diversified portfolio and strategic partnerships.

Ventas (NYSE: VTR) announced the tax treatment for its 2020 distributions, totaling $2.485 per share in taxable dividend income. This includes a previously declared fourth quarter 2019 dividend of $0.7925 per share. The fourth quarter 2020 dividend, set for payment on January 20, 2021, will impact 2021 income. Shareholders are advised to consult tax professionals concerning tax implications. Ventas, a leading REIT, operates around 1,200 properties and is positioned within the healthcare and real estate sectors.

Ventas, Inc. (NYSE: VTR) has declared a quarterly dividend of $0.45 per common share, payable in cash on January 20, 2021, to stockholders of record as of January 4, 2021. As a leading Real Estate Investment Trust (REIT), Ventas is strategically positioned in the healthcare and real estate sectors, managing approximately 1,200 properties as of September 30, 2020. The company focuses on generating consistent cash flows and superior returns through a diversified portfolio and partnerships with care providers and healthcare organizations.

Ventas, Inc. (NYSE: VTR) will present at the virtual Nareit REITworld 2020 Conference on November 17, 2020, at 9:30 a.m. ET. Written materials will be available on its website from 8 a.m. ET the same day and will be archived for a limited time. Ventas is a leading Real Estate Investment Trust operating in the healthcare sector, with a diversified portfolio of nearly 1,200 properties as of September 30, 2020. The company focuses on producing consistent cash flows and superior returns while partnering with top healthcare providers and organizations.

Ventas, Inc. (NYSE: VTR) reported its third-quarter 2020 results, revealing significant impacts from the COVID-19 pandemic. Net income decreased by 87% to $0.03 per share, while reported Funds from Operations fell 23% to $0.65 per share compared to Q3 2019. Despite challenges, the company noted improvements in its Senior Housing Operating Portfolio with increased move-ins. Ventas also expanded its Research and Innovation segment, acquiring a $1 billion life science portfolio in South San Francisco. The company maintains strong liquidity with $3.2 billion available for future opportunities.